According to Hualan Biological Engineering's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 23.5037. At the end of 2022 the company had a P/E ratio of 38.4.
Year | P/E ratio | Change |
---|---|---|
2022 | 38.4 | -6.06% |
2021 | 40.9 | -14.28% |
2020 | 47.7 | 24.53% |
2019 | 38.3 | 77.97% |
2018 | 21.5 | -29.4% |
2017 | 30.5 | -28.52% |
2016 | 42.6 | -1.86% |
2015 | 43.4 | 20.81% |
2014 | 35.9 | 3.09% |
2013 | 34.9 | -13.8% |
2012 | 40.4 | 4.03% |
2011 | 38.9 | -14.63% |
2010 | 45.5 | 38.82% |
2009 | 32.8 | -27.62% |
2008 | 45.3 | -52.8% |
2007 | 96.0 | 261.04% |
2006 | 26.6 | 31.67% |
2005 | 20.2 | -23.21% |
2004 | 26.3 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.